Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms (CHIME)
Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms: Randomized Controlled Trial (CHIME Trial)
The goal of this clinical trial is to find out if calisda, a digital health intervention, can help women with menopause symptoms manage their symptoms and improve their quality of life.
The main questions it aims to answer are:
- Does calisda, together with regular treatment, improve health outcomes after six months better than regular treatment alone?
- Are the positive effects of calisda already noticeable after three months?
Researchers will compare two groups:
- Intervention group: Participants use the calisda intervention and continue their usual treatment.
- Control group: Participants continue with their usual treatment only.
Participants will:
- Fill out questionnaires online at the start of the study, after 3 months, and after 6 months
- Continue with their usual treatment (both groups) and use calisda, a digital health intervention, for six months (intervention group only)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This pragmatic, two-arm randomized controlled trial evaluates the effectiveness of calisda, a certified medical device (CE-marked, risk class I), when used alongside regular treatment. The study compares the addition of this digital health intervention to treatment as usual (TAU) against TAU alone. Designed as an interactive online program, calisda incorporates recognized elements of cognitive behavioral therapy (CBT), behavior change, and patient education.
After confirming eligibility, participants are randomly assigned to one of two groups. The intervention group receives immediate access to calisda for six months alongside their usual treatment. The control group continues their regular treatment and is granted access to the intervention after a six-month waiting period.
Data is collected from both groups via online questionnaires at the start of the study, after three months, and after six months. The primary evaluation of effectiveness will be conducted at the six-month follow-up. Data collected at the three-month mark will be utilized to assess early treatment response.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Anja Specht, MSc.
- Phone Number: +49 40 3510520
- Email: anja.specht@gaia-group.com
Study Contact Backup
- Name: Clara Ekerdt, PhD
- Phone Number: +49 40 351052 135
- Email: clara.ekerdt@gaia-group.com
Study Locations
-
-
-
Hamburg, Germany
- GAIA AG
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female biological sex
- Age 40-65 years
- Diagnosis of menopause symptoms (ICD-10 code: N95.1) confirmed by a medical document
- Increased levels of menopause symptoms (MRS-II total score ≥ 14)
- Reduced menopause-specific quality of life (MENQOL total score ≥ 3)
- Stable symptom-related treatment (medication, psychotherapy, no treatment, …) for at least 60 days at the time of inclusion
- Sufficient knowledge of the German language
- Basic computer skills required for independent use of a digital intervention
- Consent to participation
Exclusion Criteria:
- Plans to change symptom-related treatment (medication, psychotherapy, …) in the upcoming 6 months after inclusion
- Current or history of any malignancy except for basal and squamous cell skin tumors
- Current HRT use
- Premature, medically induced menopause (e.g. following bilateral oophorectomy)
- Known somatic or psychiatric condition that might interfere with successful study participation (e.g. unstable neurologic or psychiatric disorder)
- Previous use of a digital intervention for menopause symptoms (including calisda) or another digital intervention developed by GAIA.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: calisda
Participants will receive access to the digital health intervention calisda in addition to TAU. |
Participants allocated to the intervention group will receive access to calisda in addition to treatment as usual (TAU). calisda is a digital health intervention designed for women with menopause symptoms, accessible through a web browser. The program focuses on treatment methods derived from cognitive behavioral therapy (CBT), health behavior change, and patient education. Topics addressed by calisda include understanding menopausal changes and symptoms, coping with hot flashes and night sweats, sleep, mood, self-acceptance and self-worth, relationship communication, as well as information on hormone therapy and complementary approaches. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their progress. Once registered, the program remains accessible for six months. |
|
No Intervention: Control group
Participants allocated to the control group will receive access to treatment as usual (TAU). |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
29-item Menopause-Specific Quality of Life Questionnaire (MENQOL; 1-week recall) total score
Time Frame: 6 months
|
The MENQOL is a patient-reported outcome measure (PROM) with 29 items. Each item uses a two-stage response format. This questionnaire consists of four domains, with varying item numbers: "vasomotor", "psychosocial", "physical" and "sexual". To obtain the total score, the mean of the domain scores is computed. Both the domain and the total scores range from 1 to 8. Higher total scores indicate greater impairment of quality of life. |
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hot Flash Related Daily Interference Scale (HFRDIS) total score
Time Frame: 6 months
|
The HFRDIS is a 10-item PROM assessing the extent to which hot flashes interfere with daily activities and overall quality of life over the past week. Each item is rated from 0 ("did not interfere") to 10 ("completely interfere"). The total score is the mean of all items and ranges from 0 to 10. Higher total scores indicate greater hot flash interference and thus a worse outcome, whereas lower scores indicate less interference and a better outcome. |
6 months
|
|
Insomnia Severity Index (ISI) total score
Time Frame: 6 months
|
The ISI is a 7-item PROM assessing the nature, severity, and impact of insomnia. Each item is rated on a 5-point scale from 0 to 4. The total score is the sum of all items and ranges from 0 to 28. Higher total scores indicate greater insomnia severity and thus a worse outcome, whereas lower scores indicate less insomnia severity and a better outcome. |
6 months
|
|
Patient Health Questionnaire (PHQ-9) total score
Time Frame: 6 months
|
The PHQ-9 is a 9-item PROM assessing the severity of depressive symptoms. Each item is scored from 0 ("not at all") to 3 ("nearly every day"). The total score is the sum of all items and ranges from 0 to 27. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome. |
6 months
|
|
Menopause Rating Scale II (MRS-II) total score
Time Frame: 6 months
|
The MRS-II is an 11-item PROM assessing the severity of menopause-related symptoms. Each item is rated from 0 ("no complaints") to 4 ("very severe symptoms"). The total score is the sum of all items and ranges from 0 to 44. Higher total scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome. |
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Philipp Klein, Prof. Dr. med., Universität zu Lübeck, Zentrum für Integrative Psychiatrie ZiP gGmbH
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- calisda RCT 2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.